Results 11 to 20 of about 4,584 (134)

Proinflammatory Epstein-Barr Virus Antibody Functions Track with Disease Activity in Multiple Sclerosis. [PDF]

Ann Neurol
Objective Epstein–Barr virus (EBV) has been implicated in the pathogenesis of multiple sclerosis (MS). Elevated immunoglobulin G (IgG) titers against EBV nuclear antigen 1 (EBNA1) represent the most consistent serological marker of MS risk, with levels remaining persistently elevated following disease onset.
Behrens M, Terroba-Navajas P, Willemse EAJ, Schädelin S, Comabella M, Münz C, Lauc G, Bartsch Y, Kuhle J, Lünemann JD.   +9 more
europepmc   +2 more sources

Efficacy of high-frequency low-dose rituximab and acalabrutinib in chronic lymphocytic leukemia. [PDF]

Hemasphere
Abstract Anti‐CD20 monoclonal antibodies (mAbs) are effective but not curative treatment for chronic lymphocytic leukemia (CLL). To study rituximab efficacy, we examined serial blood samples from CLL patients receiving initial monotherapy with high‐frequency low‐dose (HFLD) rituximab for 1 week followed by the addition of acalabrutinib.
Chu CC, Heffernan CB, Jaimes-Delgadillo NC, Herne CA, Bruno JE, Baran AM, Ashton JM, Mosmann TR, Barr PM, Taylor RP, Elliott MR, Zent CS.   +11 more
europepmc   +2 more sources

Development of an antibody-dependent cellular phagocytosis (ADCP) gene signature to predict prognosis in hepatocellular carcinoma 

, 2023
Abstract It remains unclear whether ADCP-related genes are linked to the prognosis of hepatocellular carcinoma (HCC). We obtained RNA-seq data and relevant clinical information on HCC from The Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium (ICGC) databases.
Junying Wang, Xi Zhu, Xiaoming Kao, Yazhou Wen   +3 more
openaire   +1 more source

Cancer cell-selective ectopic expression of CD20 as an antigen enables rituximab repurposing for solid tumour immunotherapy. [PDF]

Clin Transl Med
A recombinant AAV delivered tumour gene therapy. NF‐κB drives tumour‐selective antigen (e.g., CD20) expression. Ectopic CD20 enables rituximab repurposing to solid tumours. ADCC, ADCP, and CDC contribute to the antitumour activity. Abstract Background Despite the clinical success of cancer immunotherapies, their efficacy is often compromised by antigen‐
Kong Z, Wang Y, Zhao Y, Wang L, Fan Z, Shu Y, Wang J.   +6 more
europepmc   +2 more sources

Enhanced neutralization potency of an identical HIV neutralizing antibody expressed as different isotypes is achieved through genetically distinct mechanisms

Scientific Reports, 2022
Antibodies with the same variable region can exist as multiple isotypes with varying neutralization potencies, though the mechanism for this is not fully defined.
Thandeka Moyo-Gwete, Cathrine Scheepers, Zanele Makhado, Prudence Kgagudi, Nonkululeko B. Mzindle, Rutendo Ziki, Sharon Madzorera, Nelia P. Manamela, Frances Ayres, Bronwen E. Lambson, Simone I. Richardson, Lynn Morris, Penny L. Moore   +12 more
doaj   +1 more source

Counteracting Influenza Virus Evolution Through the Full Spectrum of Broadly Protective Antibodies. [PDF]

Immunol Rev
ABSTRACT Despite the presence of licensed vaccines and therapeutics, influenza viruses remain a major public health concern, as they cause seasonal respiratory infections and pose a pandemic threat through the emergence of zoonotic strains. Although neutralizing antibodies elicited by seasonal vaccination constitute a primary defense against infection,
Adachi Y, Takahashi Y.
europepmc   +2 more sources

Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages

Frontiers in Immunology, 2022
Antibody-dependent cellular phagocytosis (ADCP) by macrophages, an important effector function of tumor targeting antibodies, is hampered by ‘Don´t Eat Me!’ signals such as CD47 expressed by cancer cells.
Tobias Zeller, Sebastian Lutz, Ira A. Münnich, Roland Windisch, Patricia Hilger, Tobias Herold, Tobias Herold, Tobias Herold, Natyra Tahiri, Jan C. Banck, Oliver Weigert, Oliver Weigert, Oliver Weigert, Andreas Moosmann, Andreas Moosmann, Andreas Moosmann, Michael von Bergwelt-Baildon, Michael von Bergwelt-Baildon, Michael von Bergwelt-Baildon, Cindy Flamann, Heiko Bruns, Christian Wichmann, Niklas Baumann, Thomas Valerius, Denis M. Schewe, Matthias Peipp, Thies Rösner, Andreas Humpe, Christian Kellner   +28 more
doaj   +1 more source

CD16A-Specific Tetravalent Bispecific Immune Cell Engagers Potently Induce Antibody-Dependent Cellular Phagocytosis (ADCP) on Macrophages

Blood, 2018
Abstract Introduction Affimed has developed high affinity tetravalent bispecific immune cell engagers for redirected optimized cell killing (ROCK platform). Using anti-CD16A and anti-tumor target-specific antibody domains, the engagers activate NK cells to efficiently kill target cells.
Susanne Wingert, Uwe Reusch, Armin Beez, Jens Pahl, Adelheid Cerwenka, Joachim Koch, Martin Treder   +6 more
openaire   +1 more source

Drug Resistance in Multiple Myeloma: Tumor-Intrinsic Mechanisms and the Bone Marrow Microenvironment. [PDF]

Cell Biochem Funct
ABSTRACT Multiple myeloma (MM) is a malignant plasma cell disorder, and despite substantial improvements in prognosis achieved through chemotherapy, immunotherapy, and autologous stem cell transplantation, most patients ultimately develop relapsed or refractory disease. Drug resistance (DR) is increasingly recognized as a dynamically evolving ecosystem
Chen Y, Huang W, Tang M, Wang X.
europepmc   +2 more sources

Targeting a membrane-proximal epitope on mesothelin increases the tumoricidal activity of a bispecific antibody blocking CD47 on mesothelin-positive tumors

mAbs, 2020
Mesothelin (MSLN) is a cell surface glycoprotein overexpressed in several solid malignancies, including gastric, lung, mesothelioma, pancreatic and ovarian cancers.
Eric Hatterer, Xavier Chauchet, Françoise Richard, Leticia Barba, Valéry Moine, Laurence Chatel, Lucile Broyer, Guillemette Pontini, Tereza Bautzova, Flora Juan, Sebastien Calloud, Nicolas Bosson, Maud Charreton, Krzysztof Masternak, Vanessa Buatois, Limin Shang   +15 more
doaj   +1 more source